PIPA: a phase Ib study of beta-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer
Authors
Pascual, JMacPherson, IR
Armstrong, Anne C
Ward, SE
Parmar, M
Turner, AJ
Bye, H
Proszek, P
Dodson, A
Garcia-Murillas, I
King, J
Hall, E
Finneran, L
Lopez, JS
Okines, AFC
Ring, AE
Turner, NC
Affiliation
Royal Marsden Hospital and The Institute of Cancer Research, LondonIssue Date
2019
Metadata
Show full item recordCitation
Pascual J, MacPherson IR, Armstrong AC, Ward SE, Parmar M, Turner AJ, et al. PIPA: a phase Ib study of ?-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer. J Clin Oncol. 2019;37(15_suppl):1051-.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2019.37.15_suppl.1051Additional Links
https://dx.doi.org/10.1200/JCO.2019.37.15_suppl.1051Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2019.37.15_suppl.1051